Lord’s Mark subsidiary Lord’s Med receives its first approval from FDA Ghana

 Mumbai: Lord’s Mark Group, one of the leading diversified conglomerate with fast growing pharmaceutical and healthcare business has announced the export of medicines to Ghana, one of the leading markets in Africa. FDA Ghana has approved Lord’s Med, the healthcare and pharmaceutical subsidiary of the Lord’s Group, to export medicines and essential drugs. It has received approval on Lordsmol Plus Tab, Lordscold Tab, Lordsmol Tab, Metlord 500 Tab and Lordscee Tab medicines.

Speaking on the occasion Mr. Sachidanand Upadhyay, Director, Lord’s Mark Group, said “Indian Pharma sector export has exceeded USD 17 billion and 20% of it is exported to African countries. The African pharma market is expected to grow the rate of 5.9% YoY to become USD 25 billion by 2022. Ghana is one of the prominent markets growing at the fastest rate. Hence, it is a great opportunity and window for entering into the Africa market. We plan to appoint our partners and distribution channel across Africa market. However, in the initial stages we are directly doing business with our clients. We intend to generate 20% of revenue from export.”

“Lord’s Med is focused on export of medicines and in future will also focus on exporting the IVD kits to these markets. The affordable health care is a looming concern in the African market, hence Lord’s intend to offer the products at affordable price. This will be achieved through innovation in distribution strategy, removing the middle man and by investing more or R&D. Lord’s Mark is going to start its office very soon in all prominent African markets.”

 Lord’s Mark Group follows the principle of “leaving no one behind” stated by the United Nations. Lord’s Mark via its LordsMed vertical is committed to make Bharat and the world a better place w.r.t good health and well-being (SDG-Goal 3) and access to clean water and sanitation (SDG- Goal 6).